Approximately 20-25% of all cancers result from infectious agents, with the majority of these malignancies being virus-associated cancers. The Virology Program focuses on deciphering the basic mechanisms related to how human tumor viruses are linked to the development of malignancies with the goal of generating new specific therapies for cancer and for vaccines against these viruses. There are five programmatic themes in the Virology Program. These include (i) Viruses and Immunity (ii) Virus-Cell Interactions (iii) Viral Pathogenesis and Tumorigenesis (iv) AIDS-associated cancers and (v) Clinical & Translational Virology. These themes address the effects of viral infection on innate immunity and inflammation and the mechanisms by which viruses promote tumorigenesis with the ultimate goal being to develop new therapies for treating viral cancers and vaccines against oncogenic viruses. Some discoveries include the finding that virus-infected cells secrete exosomes which modulate the tumor environment, that viral-encoded microRNAs contribute to the development of neoplasms, that oncogenic viruses can blunt innate immune recognition by the host cell, and that new therapies for AIDS-associated cancers targeting cell signaling pathways are efficacious. The program is jointly led by Nancy Raab-Traub, PhD, Sarah Graham Kenan Professor of Microbiology & Immunology who is world renowned for her work on Epstein-Barr virus and associated cancers, and Blossom Damania, PhD, Assistant Dean of Research and Professor of Microbiology & Immunology, whose expertise on innate immunity and oncogenic viruses is well recognized. There are 19 program members from 6 different departments across campus. The Virology Program has recruited three new faculty since 2010: Cary Moody, Nat Moorman and Stan Lemon. During the last funding period, program members have published 343 cancer-related articles (24% collaborative). In 2014, our program members held 58 grants and $18.9M (total cost) in annual extramural funding, including 21 grants and $6M (total costs) from the NCI.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-43
Application #
9614925
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lianga, Noel; Doré, Carole; Kennedy, Erin K et al. (2018) Cdk1 phosphorylation of Esp1/Separase functions with PP2A and Slk19 to regulate pericentric Cohesin and anaphase onset. PLoS Genet 14:e1007029
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Dhungel, Bal Mukunda; Montgomery, Nathan D; Painschab, Matthew S et al. (2018) 'Discovering' primary effusion lymphoma in Malawi. AIDS 32:2264-2266
Cameron, Jennifer E; Rositch, Anne F; Vielot, Nadja A et al. (2018) Epstein-Barr Virus, High-Risk Human Papillomavirus and Abnormal Cervical Cytology in a Prospective Cohort of African Female Sex Workers. Sex Transm Dis 45:666-672
Lim, Joseph K; Liapakis, Ann Marie; Shiffman, Mitchell L et al. (2018) Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 16:1811-1819.e4
Wang, Gary P; Terrault, Norah; Reeves, Jacqueline D et al. (2018) Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci Rep 8:3199
Phillips, Bonnie; Van Rompay, Koen K A; Rodriguez-Nieves, Jennifer et al. (2018) Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. J Virol 92:
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Galanis, Evanthia; Anderson, S Keith; Miller, C Ryan et al. (2018) Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol 20:546-556
Agle, Kimberle; Vincent, Benjamin G; Piper, Clint et al. (2018) Bim regulates the survival and suppressive capability of CD8+ FOXP3+ regulatory T cells during murine GVHD. Blood 132:435-447

Showing the most recent 10 out of 1525 publications